December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

127.49 -4.97 (-3.75%)
Official Closing Price Updated: 7:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,774,050
Open 129.78
Bid (Size) 127.10 (5)
Ask (Size) 127.88 (2)
Prev. Close 132.46
Today's Range 126.85 - 130.13
52wk Range 78.19 - 148.15
Shares Outstanding N/A
Dividend Yield 1.39%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Unstoppable Stocks to Buy in August
It's not hard to envision how all three of these stocks can deliver exceptional growth. 
Via The Motley Fool
Eli Lilly vs Novo Nordisk: A Recent Study Suggests This Company Has the Best Weight Loss Drug
These healthcare stocks are up more than 400% in the past five years, thanks to their dominance in the anti-obesity market. 
Via The Motley Fool

Performance

YTD
+24.86%
+24.86%
1 Month
-10.45%
-10.45%
3 Month
+2.33%
+2.33%
6 Month
+7.80%
+7.80%
1 Year
+62.82%
+62.82%

More News

Read More
Using Weight Loss Medications Such As Wegovy, Zepbound? Psychologist Warns Of Linked Eating Disorder Risks
Via Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,600 Today
Via Benzinga
Hims & Hers Stock Is Looking to Cash in From the GLP-1 Hype, but Will Its Controversial Strategy Pay Off?
Via The Motley Fool
Smart Money Is Betting Big In NVO Options
Via Benzinga
As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott
Via Investor's Business Daily
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
Via The Motley Fool
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
Via The Motley Fool
Why Eli Lilly Stock Trounced the Market on Thursday
Via The Motley Fool
What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.
Via InvestorPlace
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
Via The Motley Fool
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
Via The Motley Fool
The Top 7 Stocks to Buy Now: Summer 2024
Via InvestorPlace
FDA Warns Of Overdose Risks With Compounded Wegovy, Ozempic Injections
Via Benzinga
Exposures Product Safety
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
Via Benzinga
Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds
Via Benzinga
NYSE:NVO stands out as a growth opportunity that won't break the bank.
Via Chartmill
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
Via The Motley Fool
3 Overlooked Stocks Poised for a Breakout Very Soon
Via InvestorPlace
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
Via The Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Via The Motley Fool
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Via The Motley Fool
This Could Send Ozempic's Sales Potential to a Whole Other Level
Via The Motley Fool
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.